Given the discrepancy between IHC-based ER status and expression-based ER status, we reasoned that some of the variation seen in the clinical benefit from tamoxifen treatment may be partially attributable to true ER negative tumours being misclassified as ER positive. Here, ESR1 is linked to neoplasm.